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Abstract
Background: Several children with autism show regression in language and social development while maintaining normal
motor milestones. A clear period of normal development followed by regression and subsequent improvement with
treatment, suggests a multifactorial etiology. The role of inflammation in autism is now a major area of study. Viral and
bacterial infections, hypoxia, or medication could affect both foetus and infant. These stressors could upregulate
transcription factors like nuclear factor kappa B (NF-kB), a master switch for many genes including some implicated in
autism like tumor necrosis factor (TNF). On this hypothesis, it was proposed to determine NF-kB in children with autism.
Methods: Peripheral blood samples of 67 children with autism and 29 control children were evaluated for NF-kB using
electrophoretic mobility shift assay (EMSA). A phosphor imaging technique was used to quantify values. The fold increase
over the control sample was calculated and statistical analysis was carried out using SPSS 15.
Results: We have noted significant increase in NF-kB DNA binding activity in peripheral blood samples of children with
autism. When the fold increase of NF-kB in cases (n=67) was compared with that of controls (n=29), there was a significant
difference (3.14 vs. 1.40, respectively; p,0.02).
Conclusion: This finding has immense value in understanding many of the known biochemical changes reported in autism.
As NF-kB is a response to stressors of several kinds and a master switch for many genes, autism may then arise at least in
part from an NF-kB pathway gone awry.
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Introduction
Autism is a severe developmental disorder of childhood.
Children with autism demonstrate deficits in social interaction,
verbal and nonverbal communication, and repetitive behaviors or
interests. Incidence figures range from 4 per 10,000 in 1984 to
16.8 per 10,000 in 2001 [1]. The condition, first described by Leo
Kanner (1943), is still diagnosed on the basis of symptoms using
the Diagnostic and Statistical Manual 4
th edition (DSM IV)
Criteria for Autism [2,3]. Generally 20–25% of cases are
considered to be of the regressive type, wherein parents report a
period of normal or near normal development followed by
developmental plateauing or regression [1]. Lord et al. (2004)
reported that 40% of children with autism have regressive autism
[4]. The etiology of autism continues to be debated.
Inflammation is now one of the major areas of study in autism.
Licinio in an Editorial in ‘Molecular Psychiatry’ suggested that in
future there will be a sub category of ‘Autoimmune autism’ within
the autism spectrum [5]. Jyonouchi and others (2001) studied
proinflammatory and regulatory cytokines to understand innate and
adaptive immune responses in children with autism who had
developmental regression [6]. Peripheral blood mononuclear cells
(PBMCs) were stimulated with lipopolysaccharide (LPS) in three
groups of children – Children with Autism Spectrum Disorder
(ASD), normal siblings, and controls. The ASD group produced
significantly more proinflammatory cytokines namely, tumor
necrosis factor a (TNFaand interleukins, especially IL-1ß and IL-
6. In some children the ratio of proinflammatory/counter-
inflammatory cytokines, TNFa/TNFRII (tumor necrosis factor
receptor II) was also higher. This could imply aberrant innate
responses. IL-10 production was lower in PBMCs stimulated with
IL-18. This suggests a dysregulation of the adaptive immune
mechanism as well [6,7]. An important recent review ‘‘The immune
system’s role in the biology of autism’’ has highlighted the role of
immune system dysfunction in autism. Among the cytokines studied,
levels of transforming growth factor beta (TGFb) were reduced in
plasma, while levels of macrophage inhibitory factor (MIF) were
increased. Lower levels of immunoglobulins, differences in gene
expression related to natural killer cell activity and altered monocyte
cytokine responses to Toll-like receptor (TLR) stimulation, have all
been documented in ASD. Much work has been done on circulating
maternal antibodies directed towards brain proteins [8].
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alterations in its activity could explain many of these observations.
David Baltimore, in whose laboratory NF-kB was first discovered,
states ‘‘In 1986, my laboratory was searching for transcription
factors that might control the activation of the kappa immuno-
globulin light chain when we came across NF-kB. We thought it
was specific to B-lymphocytes and never imagined that it would
turn out to be among the most protean of transcription factors ever
discovered – ready to be activated by a wide range of inducing
stimuli’’ [9]. Under normal conditions, NF-kB is present in the
cytoplasm as an inactive heterotrimer (Figure 1). Stimulation with
a specific inducer, such as TNFa, activates an IkB kinase complex
(IKKs), triggering its degradation and allowing free NF-kBt o
translocate to the nucleus and activate gene expression [10–12].
NF-kB activity is needed for proper immune system function while
constitutive activation of NF-kB pathway is associated with
malignancies and various inflammatory diseases [11,13]. This
transcription factor in turn is a master switch for many genes,
including some implicated in autism like tumor necrosis factor
(TNF) [11–13]. Moreover, oxidative stress leads to increase in
reactive oxygen species (ROS) which activates IKKs that
phosphorylate IkBa for proteasomal degradation [14]. When
ROS is inhibited, the activation of NF-kB is abrogated [15,16].
Oxidative stress has been shown to contribute to the etio
pathology of various disorders including autism. In a recent study,
cerebellar levels of 3-nitrotyrosine, a known marker for oxidative
stress, were found to be significantly increased in autism [17].
Chez et al reported that TNFa,a potent inducer of NF-kB, was
significantly higher in the cerebrospinal fluid of children with
autism [18].
Children diagnosed with autism, have an over representation of
birth by Cesarean Section, neonatal nursery admissions, repeated
infections and repeated antibiotic use [19]. The impact of early life
programming and changes in transcription factors is an emerging
area of interest in neurodevelopment [20]. As several of these
factors represent different kinds of stressful events, which could up
regulate NF-kB, it was proposed to study this transcription factor.
With informed consent and with clearance from the ethics
committee of the Osmania Medical College, it was proposed to
study NF-kB DNA binding activity in children with autism and
regression, and in a group of control children matched for age.
The objectives were to understand the role of NF-kB in childhood
autism in 50 children and 30 controls. In this study, we have noted
a significant increase in NF-kB DNA binding activity in peripheral
blood samples of children with autism. When fold increase of NF-
kB in children with autism was compared with that of age
matched controls, there was a significant difference between the
two groups.
Results
The number of cases on which NF-kB detection (both DNA
binding and fold of activation of DNA binding) was completed
with controls for comparison was 67 children (Fig. 2). The overall
fold activation of NF-kB is depicted in Figure 3.
As shown in Table 1 the total number of cases with autism was
67. There were 29 age matched controls and 2 adult controls.
Three children had recovered symptom wise from autism and
were no longer autistic on the Childhood Autism Rating Scale
(CARS) and were tested to compare values of markers [21].
Of the cases, there were 64 males and 3 females. The usual ratio
reported is 5–6 males per affected female. The controls were more
equally distributed. The mean ages ranged from 18 months to ten
years with 4.14 years for cases and 4.05 years for controls.
Four sets of data were analyzed -
A. Using the data from the current study with 67 cases and 29
age matched controls.
B. 67 cases and 29 age matched controls plus two adult controls
- a total of 31 controls.
C. Data, excluding four cases which caused skew by exception-
ally high values - 63 cases and 31 controls (Fig. 2B).
D. Three children, those no longer tested as autistic on CARS,
were evaluated against the autistic group. Details are
provided in Text S1. Two children had completed five years
of treatment each and one child was on treatment for three
years when the samples were collected.
The mean fold intensities were 3.1408 for cases and 1.3980 for
controls (Table 2). This is also depicted in Figure 3. The mean fold
increase was statistically significant between cases and controls
(p,0.02) using the Mann Whitney U Test (Table 2). The variances
of fold increase were significantly different among the groups
therefore the Mann Whitney U Test was used to compare mean
values. The mean rank for cases was 52.85 and the mean rank for
controls was 38.45. This difference was significant (p,0.02).
In all the four sets of data, statistical analysis was significant. A
larger sample in group D would be very gratifying to work with.
The details of statistical analysis of groups B, C, and D are in the
Text S1.
Discussion
Nuclear transcription factor kappaB is a stress inducible
transcription factor. We have provided data to support the role
of NF-kB in autism. No control study has been reported on NF-kB
in children with autism to the best of our knowledge. In our study,
we have found that there was a significant increase in the amount
of NF-kB in samples from children with autism when compared
with those from age matched controls. Studies are beginning to
document that recovery or ‘‘optimal development’’ bringing the
child out of the autism spectrum, is possible [22,23]. Our finding
in three recovered children needs further evaluation in this
context.
Elevated amounts of NF-kB in children with autism can
strengthen the conceptual frameworks of the role of innate
immunity and ROS in the etiopathology of this condition. A new
Figure 1. Composition of NF-kB band. Nuclear extracts from
untreated and TNF-stimulated cells were detected by gel shift assay and
showed different dimers of NF-kB.
doi:10.1371/journal.pone.0019488.g001
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Environment) has found a significant increase in a number of
cytokines in plasma including IL-1b, IL-6, IL-8, and IL-12 p40 in
an ASD group compared with typically developing controls [24].
All of these cytokines are known to be regulated by NF-kB [11].
Using a proteomic approach Shen et al. (2010) found that in a
multiplex family with autism, the amount of p52 was increased
without change in the amount of IkBa and postulated that NF-kB
could be activated in a non-canonical manner [25]. However, the
authors did not evaluate the activity of NF-kB in the nucleus. The
most important study of inflammatory markers in autism comes
from an autopsy series [26,27]. Macrophage chemoattractant
protein (MCP-1) and tumor growth factor beta-1 (TGFb-1),
known neuroinflammatory markers, were found to be consistently
increased [26,27]. For example, the ligand for Fms-related
tyrosine kinase 3 (Flt3), a VEGF receptor, known to promote
the proliferation and mobilization of hematopoietic cells is an NF-
kB-dependent gene and elevated levels were found in brain tissue
Figure 2. Amount of NF-kB DNA binding of cases, controls, and recovered (R1) children. PBMC were separated from fresh peripheral
blood of children with autism and age matched controls by 2.5% gelatin sedimentation followed by Ficoll-paque density gradient centrifugation. The
pellet was used to prepare nuclear and cytoplasmic extracts. 8 mg of nuclear extract was assayed for NF-kB DNA binding using EMSA. Radioactive
bands were detected from dried gel after exposure in the Phosphorscreen. The amounts of NF-kB DNA binding (A, left upper panel) and the fold
increase (A, left lower panel) of 4 cases (02–05), 2 controls (C1 and C2) and 1 recovered (R1) were indicated. The amounts of NF-kB DNA binding (B,
right upper panel) and the fold increase (B, right lower panel) of 4 cases (15–18) and 2 controls (C8 and C9) were indicated. Similarly, the amounts of
NF-kB DNA binding (C, left panel) and the fold increase (C, right panel) of 9 cases (22–30) and 4 controls (C12–C15) were indicated.
doi:10.1371/journal.pone.0019488.g002
Figure 3. The mean fold intensities of NF-kB DNA binding in
cases and controls. 67 cases (mean fold intensity is 3.1408) and 29
age matched controls (mean fold intensity is 1.398) p,0.02 is depicted.
doi:10.1371/journal.pone.0019488.g003
Table 1. Frequency distribution, age and gender.
Number Mean Age Males Females
Cases 67 4.1424 64 3
Controls 29 4.0513 19 8
‘Recovered Cases’ 37 . 0 3 -
Adult Controls 23 5 - 2
Total 101
doi:10.1371/journal.pone.0019488.t001
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major regulator of innate immunity and these cytokines have been
found to be up regulated by NF-kB, our finding of significant
elevation of this transcription factor becomes even more relevant.
An important mechanism of activation of NF-kB is through the
production of ROS. ROS generation is relatedto stresswhich could
be due to multiple environmental, behavioral, and concomitant
illness factors [29]. Impaired methylation and increased oxidative
stress have been found in children with autism [30]. More recently,
the oxidative stress marker 3-nitrotyrosine (3-NT) was reported to
be significantly elevated in cerebellar tissue homogenates of
individuals with autism when compared to normal controls [17].
The presence of markers of oxidative stress,known to modulate NF-
kB, in brain tissue of individuals with autism is an important
correlation. Children with autism could be in a ‘‘hyper arousal’’
state of NF-kB due to the constant effect of environmental stressors
– even fear is known to upregulate NF-kB [11]. Children with
autism may have an altered threshold to fearful stimuli.
Recently, the mechanisms underlying the termination of NF-kB
activity have been discussed [31,32]. Children with autism may be
unable to turn off stress induced responses. Terminating NF-kB
activity is dependent on any of several downstream modulators.
These operate variously through altered cofactor binding, degra-
dation and displacement of NF-kB from DNA. These modulators
are worth studying like the suppressor of cytokine signaling 1
(SOCS1) and several inhibitors of the IkB family. TNFa has been
shown to be in excess in the serum and CSF of individuals with
autism [33]. It is known to be a potent inducer of NF-kB and is also
in turn unregulated by NF-kB. Azadirachtin, derived from neem,
has recently been shown to block TNF-induced biological responses
by inhibiting ligand binding [34]. Drugs like this could be of
potential use in autism. Conversely, identifying agents that increase
NF-kB in children and regulating these triggers, would go a long
way in preventing a certain sub sect of regressive autism.
NF-kB has rightly been called a double edged sword, both
needed by the body in its defense and producing disease when
inappropriately activated. To conclude, several neurological and
inflammatory disorders have been linked to NF-kB. Autism, our
results tell us, now appears to have joined their ranks.
Materials and Methods
Clearance from the Ethics committee of the Osmania
Medical College
Clearance was taken from the ethics Committee of the Medical
College before commencement of the study, to draw blood
samples (3 ml from each child), of children with autism and from
control children.
Selection of cases
Cases attending the Department of Child Psychiatry, Niloufer
Hospital were screened for features of autism. Each child was
assessed by the same team, comprising a psychiatrist, clinical
psychologist and psychiatric social worker. Children who fulfilled
DSM IV criteria were further assessed for regression. Regression
was defined, here as a loss of previously achieved milestones in
language, personal or social development or in adaptive skills.
Children with regression in motor milestones were excluded. All
children presented to us after several months of regression. The
manner in which regression was assessed is detailed in Text S2.
Children were selected as cases, if
N they fulfilled DSM IV criteria,
N had normal motor milestones, but had regressed in at least one
other area of development,
N were aged between 18 months and 10 years,
N parents were ready to participate in the study, and ready to
sign the consent form.
Selection of controls *
Children were selected as controls if –
N they were age matched,
N from the same family,
N did not show other abnormalities on a questionnaire to exclude
psychiatric disorders,
N had normal motor milestones,
N were aged between 18 months and 10 years,
N parents were ready to participate in the study, and ready to
sign the consent form
* One of the problems we faced was that most children were
single and while there was no shortage of referred cases, it was
difficult obtaining controls. All controls were either siblings or
cousins of the affected child. The children were matched for age
and socioeconomic status but not for gender. The Consent form is
detailed in Text S3. There were 29 age matched controls and 2
adult controls. The adults were taken as controls, on two occasions,
when scheduled control children did not show up and the samples
of children with autism would otherwise have been wasted.
Table 2. Mean fold intensity of NF-kB DNA binding in children with autism (cases) vs. without autism (controls).
Groups Cases Controls p value
A 67 cases and 29 age matched, controls 3.1408 1.3980 0.02
B 67 cases and 31 controls(2 Adults) 3.1408 1.3723 0.01
C Data excluding four cases causing a skew in data by exceptionally high values
63 cases and 31 controls
2.0464 1.3723 0.028
D Three recovered’ cases and 67 cases
When tested on CARS
Cases Recovered
3.1408 0.7741 0.026
Comparison of mean fold intensities between groups by Non parametric test of ‘Mann-Whitney U’ was used.
Childhood Autism Rating Scale (CARS) [21].
doi:10.1371/journal.pone.0019488.t002
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3 ml blood was drawn in Na-EDTA vials and used for
experiments.
Test procedures
Isolation of PBMC and neutrophils from human
blood. Neutrophils and peripheral blood mononuclear cells
(PBMC) were separated from fresh peripheral blood by 2.5%
gelatin sedimentation followed by ficoll-paque (Histopaque-1077)
density gradient centrifugation method. The EDTA-blood was
incubated with 2.5% gelatin (in saline) solution in saline with 1:1
ratio at 37uC for 30 minutes. The erythrocytes (RBC) were
sedimented in 30 minutes as these cells formed rouleaux. The
RBC-free upper layer (rich with leukocytes and platelets) formed
above the Histopaque and was centrifuged at 7006g for 30 min.
This layer (PBMC) was carefully removed by aspiration,
suspended in phosphate buffer saline (PBS) and centrifuged at
15006g for 5 minutes. The pellet was washed twice with PBS and
then used to prepare cytoplasmic and nuclear extracts.
Electrophoretic mobility shift assay (EMSA). PBMC
were assayed for NF-kB activation using EMSA (electrophoretic
mobility shift assay). Cells were suspended in 0.4 ml of lysis buffer
(10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM DTT, 0.5 mM PMSF, 2 mg/ml leupeptin and
2 mg/ml aprotinin and incubated on ice for 15 min, after which
12.5 ml of 10% Nonidet P-40 was added. The tube was then
vigorously shaken on a vortex machine for 10 s, and the
homogenate centrifuged at maximum speed for 30 s in a
microfuge. The nuclear pellet was re-suspended in 25 ml of ice-
cold nuclear extraction buffer (20 mM HEPES (pH 7.9), 0.4 M
NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF,
2.0 mg/ml leupeptin and 2.0 mg/ml aprotinin). The tube was
incubated on ice for 30 min with intermittent mixing and finally
centrifuged for 5 min in a microfuge at 4uC, and the supernatant
(nuclear extract) collected. 8 mg of nuclear extract was incubated
in a mixture containing 2 mg of poly dI:dC in a binding buffer
(25 mM HEPES pH 7.9, 0.5 mM EDTA, 0.5 mM DTT, 1%
Nonidet P-40, 5% glycerol, and 50 mM NaCl) with double-
stranded oligonucleotide of NF-kB. EMSA was performed in
native gel. The gel was dried and exposed in a phosphor screen
and scanned in a Phosphor Imager (Fuji Photo Film, Japan).
Quantification of intensity
The software used for quantification was Image Quant 5.2. To
quantify the intensity, an equal area was selected from each lane
and the value from the free probe lane (without any sample/
negative control/only the radioactive master mix) was subtracted
from the test lanes. To deduce the fold intensity, the lowest control
value was taken as 1 fold. The patient values were divided by the
control values to obtain fold values. Some of the controls also had
high values. However, all control values were included in
calculation of the mean for the control group and in statistical
analysis.
Statistical Analyses
Data was analyzed using SPSS Version 15. Mean and SD
values were calculated for fold increase by groups, as shown in
Figure 2. The complete data are included in Text S4. The mean
values of fold increase among groups were compared using student
t- test and the Mann Whitney U Test as the variance between
groups was high.
Statistical tests used were both parametric and non parametric
as data was skewed.
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